Description
What is Tesamorelin?
Tesamorelin is a synthetic analog of the body’s own Growth Hormone Releasing Hormone (GHRH). It works by stimulating the pituitary gland to produce and release growth hormone naturally — in the body’s own pulsatile rhythm rather than introducing synthetic GH directly.
What makes Tesamorelin particularly noteworthy is that it achieved FDA approval (under the brand name Egrifta) for the reduction of excess abdominal fat in HIV-associated lipodystrophy — making it one of the few GH-stimulating peptides with a full regulatory approval and a robust clinical trial programme behind it.
What Researchers Are Exploring
Abdominal Fat & Body Composition Tesamorelin’s most well-established research area is its ability to reduce visceral (deep abdominal) fat. Clinical trials showed significant reductions in abdominal fat in study participants — without the metabolic side effects sometimes seen with direct GH administration. This makes it particularly relevant for body composition and metabolic health research.
Growth Hormone Stimulation As a GHRH analog, Tesamorelin stimulates natural GH production from the pituitary. Research has shown it elevates GH and IGF-1 levels in a physiologically natural pattern — important for researchers studying GH’s downstream effects on muscle, fat, bone, and recovery.
Cognitive & Neuroprotective Research An emerging and exciting area of Tesamorelin research involves cognition. Studies have explored its potential to improve cognitive function — possibly mediated through GH/IGF-1 effects on the brain — with some research suggesting benefits for memory and executive function.
Metabolic Health Research has explored Tesamorelin’s broader metabolic effects including improvements in lipid profiles, insulin sensitivity, and inflammatory markers — effects that extend beyond fat reduction.
Worth Noting Tesamorelin’s FDA approval gives it a clinical credibility that most peptides don’t have. The regulatory-grade clinical trial data behind it provides researchers with a level of confidence in its pharmacological profile that few other GH-related peptides can match.
For research use only. Not intended for human consumption. Not approved by the FDA or TGA.
Field Details Peptide Name Tesamorelin Also Known As Egrifta (FDA-approved brand) CAS Number 218949-48-5 Molecular Formula C221H366N72O67S Molecular Weight 5135.9 Da Sequence 44 amino acid GHRH analog with N-terminal trans-3-hexenoic acid modification Receptor Target GHRH receptor (pituitary) Regulatory Status FDA-approved for HIV-associated lipodystrophy Purity ≥98% (HPLC verified) Format Lyophilised powder Amount per Vial 10mg Appearance White to off-white powder
Before Reconstitution: Store at -20°C long-term, or 2-8°C for up to 3 months.
After Reconstitution: Store at 2-8°C. Use within 30-45 days. Do not freeze.
Suggested Reconstitution: Add 2ml bacteriostatic water for 5mg/ml.
Supplies: Available in our Research Supplies category or as a Reconstitution Kit.